{
    "clinical_study": {
        "@rank": "85715", 
        "arm_group": [
            {
                "arm_group_label": "diclofenac diethylamine, DDEA 2.32% gel", 
                "arm_group_type": "Experimental", 
                "description": "diclofenac diethylamine, DDEA 2.32% gel"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle control"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of diclofenac DDEA 2.32 % in patient\n      suffering from knee osteoarthritis (OA)."
        }, 
        "brief_title": "Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis, Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Male or female \u2265 50 years old; 2. Symptomatic OA of one or both knees, according\n             to ACR criteria, diagnosed at least 6 months previously; 3. Pain in either knee\n             originates in the knee (not referred pain from other sites, such as hip or back) and\n             no other cause of pain than knee OA; 4. Have used oral NSAIDs or COXIBs for the knee\n             OA pain (including aspirin if \u2265 500 mg and used in this indication), at least one\n             dose per day, for not less than 10 days out of the 14 days preceding the screening\n             visit and also within the 24 hours preceding the screening visit; 5. Be able to\n             tolerate rescue medication with only 500 mg paracetamol (APAP) taken in doses of 1-2\n             tablets up to a maximum of 6 tablets (3 grams) per day for the duration of the study\n\n        Exclusion Criteria:\n\n        - 1. Partial or total replacement of either knee joint, past or planned/expected during\n        study duration.\n\n        2. OA of the knee due to other underlying conditions, such as gout, chondrocalcinosis,\n        hemochromatosis, joint infections, neuropathia, or severe traumatic joint damage (however,\n        common risk factors, such as obesity and past meniscectomy or ligament rupture and repair,\n        are allowed); 3. History of systemic inflammatory (autoimmune) disease (rheumatoid\n        arthritis, systemic psoriasis, systemic lupus erythematosus, systemic sclerosis, etc.) or\n        laboratory values indicative of such disease with subsequent diagnosis by a physician; 4.\n        Fibromyalgia within the previous year; 5. Allergy or asthma to diclofenac, APAP, aspirin,\n        other NSAIDs or any of the ingredients in the gel (i.e. isopropyl alcohol, propylene\n        glycol, or butylhydroxytoluene), or any other contraindication for the study drug or the\n        rescue medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "252", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967550", 
            "org_study_id": "194-P-308", 
            "secondary_id": "2012-004024-38"
        }, 
        "intervention": {
            "arm_group_label": "diclofenac diethylamine, DDEA 2.32% gel", 
            "intervention_name": "diclofenac diethylamine, DDEA 2.32% gel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Diclofenac"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Symptomatic knee OA Kellgren-Lawrence grade 1-3", 
        "lastchanged_date": "November 26, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Durrheim", 
                        "country": "Germany"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Hersfeld", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Novartis Clinical Project Leader", 
                    "phone": "+41223635293"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockach", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 4-week, Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Assess the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel for the Relief of Signs and Symptoms in Patients With Knee Osteoarthritis", 
        "overall_contact": {
            "last_name": "Novartis Clinical Project Leader", 
            "phone": "+41223635293"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "POM will be assessed by subject on a 100 mm Visual Analog Scale (VAS)", 
            "measure": "Measure: Pain On Movement (POM)", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "POM will be assessed by subject on a 100 mm Visual Analog Scale (VAS)", 
            "measure": "Measure POM regarding onset of efficacy", 
            "safety_issue": "No", 
            "time_frame": "6, 12, 30, 36 hours"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}